0
No votes yet
ONS Guidelines Article

Supplementary Material for ONS Guidelines™ for Opioid-Induced and Non-Opioid-Related Cancer Constipation

ONF 2020, 1-129 DOI:

Table of Contents

  1. Guideline panel conflict of interest disclosures
  2. PICO questions
  3. Evidence-to-Decision Frameworks
  • Prophylactic bowel regimen and lifestyle education vs. lifestyle education for opioid-induced constipation
  • Osmotic or stimulant laxatives and lifestyle education vs. lifestyle education for opioid-induced constipation
  • Osmotic polyethylene glycol and lifestyle education vs. lifestyle education for opioid-induced constipation
  • Methylnaltrexone (subcutaneous or oral) and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Naldemedine (0.2 mg) and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Naloxegol and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Prucalopride and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Lubiprostone and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Linaclotide and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Osmotic or stimulant laxatives and lifestyle education vs. lifestyle education for non-opioid-related constipation
  • Acupuncture and lifestyle education vs. lifestyle education for non-opioid-related constipation
  • Electroacupuncture and lifestyle education vs. lifestyle education for non-opioid-related constipation